Patent · US Active

Vibrio cholerae lipoprotein 15 (Lp15) variants as anti-interference additive in TpN17-based immunoassays for detection of anti-Treponema antibodies

US9714949B2 · kind B2 · utility

0Cited by

0References

7Claims

0Family size

Assignee

Roche Diagnostics Operations, Inc. · US

Inventors

Elke Faatz · Huglfing, DE
Peter Schaarschmidt · Ulm, DE
Urban Schmitt · Oberhausen, DE
Christian Scholz · Penzberg, DE

Key dates

Filing date	Jul 18, 2014
Grant date	Jul 25, 2017
Priority date	—
Expiry date	Jul 18, 2034

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/26
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

The invention relates to a method for detecting antibodies against the TpN17 antigen of Treponema pallidum in an isolated sample wherein a peptide sequence of Vibrio cholerae lipoprotein 15 (VcLp15) or a partial sequence thereof is used as a reagent for reduction of interference, i.e. for minimizing false positive results. In addition the invention relates to fusion polypeptides comprising a VcLp15 peptide sequence and a chaperone, to their use as an additive in an immunoassay for said reduction of interferences and for minimizing false positive results and to a reagent kit for detecting antibodies against Treponema pallidum antigens in an isolated sample comprising a TpN17 antigen and said VcLp15-chaperone fusion polypeptide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.